Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CHEK-ATP157 | Human | HEK293/Human NGFR Stable Cell Line | |||
| NGR-H5254 | Human | Human NGFR / TNFRSF16 Protein, Fc Tag (MALS verified) |  |
|
|
Expression analysis of human NGFR on HEK293/Human NGFR Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human NGFR Stable Cell Line or negative control cell using PE-labeled anti-human NGFR antibody after fixation with 4% paraformaldehyde.
Loaded Human NGFR Protein, Fc Tag (Cat. No. NGR-H5254) on Protein A Biosensor, can bind Human NT-4, Tag Free (Cat. No. NT4-H5114) with an affinity constant of 1.64 nM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
The purity of Human NGFR Protein, Fc Tag (Cat. No. NGR-H5254) is more than 95% and the molecular weight of this protein is around 115-135 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Cenegermin | rhNGF (Dompe Farmaceutici) | Approved | Dompe Farmaceutici Spa | 欧适维, Sentinel, Oxervate | EU | Keratitis | Dompé Pharmaceutici Spa | 2017-07-06 | Keratitis; Corneal Ulcer; Corneal Diseases; Dry Eye Syndromes; Retinitis Pigmentosa; Eye Diseases; Mental Disorders | Details |
| Mouse nerve growth factor (Wuhan Hiteck Bio-pharmaceutical) | Approved | Wuhan Hiteck Biological Pharma Co Ltd | 金路捷 | Mainland China | Trauma, Nervous System | Wuhan Hiteck Biological Pharma Co Ltd | 2002-01-01 | Optic Nerve Injuries; Trauma, Nervous System | Details | |
| Mouse nerve growth factor (Livzon Group) | Approved | Livzon Pharmaceutical Group Inc | 丽康乐 | Mainland China | Optic Nerve Injuries | Livzon(Group) Pharmaceutical Factory | 2010-05-07 | Optic Nerve Injuries | Details | |
| Mouse nerve growth factor (Staidson Biopharma) | Approved | Staidson(Beijing) Biopharmaceuticals Co Ltd | 苏肽生 | Mainland China | Optic Nerve Injuries | Staidson(Beijing) Biopharmaceuticals Co Ltd | 2006-04-11 | Diabetic Foot; Optic Nerve Injuries; Peripheral Nerve Injuries | Details | |
| Cenegermin | rhNGF (Dompe Farmaceutici) | Approved | Dompe Farmaceutici Spa | 欧适维, Sentinel, Oxervate | EU | Keratitis | Dompé Pharmaceutici Spa | 2017-07-06 | Keratitis; Corneal Ulcer; Corneal Diseases; Dry Eye Syndromes; Retinitis Pigmentosa; Eye Diseases; Mental Disorders | Details |
| Mouse nerve growth factor (Wuhan Hiteck Bio-pharmaceutical) | Approved | Wuhan Hiteck Biological Pharma Co Ltd | 金路捷 | Mainland China | Trauma, Nervous System | Wuhan Hiteck Biological Pharma Co Ltd | 2002-01-01 | Optic Nerve Injuries; Trauma, Nervous System | Details | |
| Mouse nerve growth factor (Livzon Group) | Approved | Livzon Pharmaceutical Group Inc | 丽康乐 | Mainland China | Optic Nerve Injuries | Livzon(Group) Pharmaceutical Factory | 2010-05-07 | Optic Nerve Injuries | Details | |
| Mouse nerve growth factor (Staidson Biopharma) | Approved | Staidson(Beijing) Biopharmaceuticals Co Ltd | 苏肽生 | Mainland China | Optic Nerve Injuries | Staidson(Beijing) Biopharmaceuticals Co Ltd | 2006-04-11 | Diabetic Foot; Optic Nerve Injuries; Peripheral Nerve Injuries | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Mouse nerve growth factor (Sinobioway Biomedicine) | Phase 3 Clinical | Sinobioway Biomedicine Co Ltd | Diabetic Foot; Optic Nerve Injuries | Details | |
| Choroid plexus cell replacement therapy (Living Cell Technologies) | Phase 3 Clinical | Living Cell Technologies | Surgical Wound Infection | Details | |
| Recombinant human nerve growth factor (Sichuan ZehaTimes Pharmaceutical) | Phase 2 Clinical | Sichuan ZehaTimes Pharmaceutical Co Ltd | Optic Nerve Injuries | Details | |
| Recombinant human nerve growth factor(Sinobioway Biomedicine) | SMR001; SMR-001 | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Xerophthalmia | Details |
| Recombinant human nerve growth factor (Xintrum Pharmacouticals) | rh-NGF | Phase 2 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Keratitis; Optic Nerve Injuries; Glaucoma, Open-Angle | Details |
| CHF-6467 | CHF-6467 | Phase 2 Clinical | Chiesi Farmaceutici SPA | Diabetic Foot | Details |
| Udonitrectag | REC-0559; MT-8; REC 0/0559 | Phase 2 Clinical | Mimetech SRL | Keratitis | Details |
| Recombinant human nerve growth factor(Chongqing Kerun Biologic) | Phase 1 Clinical | Chongqing Kerun Biologic Pharmaceutical Development Co Ltd | Keratitis | Details | |
| CD4^LVFOXP3 Treg-like cell therapy | CD4^LVFOXP3 | Phase 1 Clinical | Stanford University | Polyendocrinopathies, Autoimmune | Details |
| Beta-Nerve Growth Factor, Human (Aalborg University) | Phase 1 Clinical | Aalborg University Shakespeare Company | Pain; Hyperalgesia | Details | |
| Recombinant human nerve growth factor (Beijing Tongren Hospital) | Phase 1 Clinical | Beijing Tongren Hospital, Cmu | Optic Nerve Injuries | Details | |
| Mouse nerve growth factor (Sinobioway Biomedicine) | Phase 3 Clinical | Sinobioway Biomedicine Co Ltd | Diabetic Foot; Optic Nerve Injuries | Details | |
| Choroid plexus cell replacement therapy (Living Cell Technologies) | Phase 3 Clinical | Living Cell Technologies | Surgical Wound Infection | Details | |
| Recombinant human nerve growth factor (Sichuan ZehaTimes Pharmaceutical) | Phase 2 Clinical | Sichuan ZehaTimes Pharmaceutical Co Ltd | Optic Nerve Injuries | Details | |
| Recombinant human nerve growth factor(Sinobioway Biomedicine) | SMR001; SMR-001 | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Xerophthalmia | Details |
| Recombinant human nerve growth factor (Xintrum Pharmacouticals) | rh-NGF | Phase 2 Clinical | Jiangsu Zhongxin Pharmaceutical Co Ltd | Keratitis; Optic Nerve Injuries; Glaucoma, Open-Angle | Details |
| CHF-6467 | CHF-6467 | Phase 2 Clinical | Chiesi Farmaceutici SPA | Diabetic Foot | Details |
| Udonitrectag | REC-0559; MT-8; REC 0/0559 | Phase 2 Clinical | Mimetech SRL | Keratitis | Details |
| Recombinant human nerve growth factor(Chongqing Kerun Biologic) | Phase 1 Clinical | Chongqing Kerun Biologic Pharmaceutical Development Co Ltd | Keratitis | Details | |
| CD4^LVFOXP3 Treg-like cell therapy | CD4^LVFOXP3 | Phase 1 Clinical | Stanford University | Polyendocrinopathies, Autoimmune | Details |
| Beta-Nerve Growth Factor, Human (Aalborg University) | Phase 1 Clinical | Aalborg University Shakespeare Company | Pain; Hyperalgesia | Details | |
| Recombinant human nerve growth factor (Beijing Tongren Hospital) | Phase 1 Clinical | Beijing Tongren Hospital, Cmu | Optic Nerve Injuries | Details |
This web search service is supported by Google Inc.
A-Z
